Last reviewed · How we verify

NCT07492004: CMDR

China Monogenic Diabetes Registry

Recruiting now Last updated 25 March 2026
What this trial tests

trial testing No Interventions in Neonatal Diabetes in 5,000 participants. Currently enrolling.

Timeline
28 February 2021
Primary endpoint
31 July 2030
31 July 2030

Quick facts

Lead sponsorTianjin Medical University General Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment5,000
Start date28 February 2021
Primary completion31 July 2030
Estimated completion31 July 2030
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Medical University General Hospital

Who can join

Eligibility, any sex, with Neonatal Diabetes or Monogenic Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to: Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution Participants will: * Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Interventions

Trials testing the same drug.

Other recruiting trials for Neonatal Diabetes

Currently open trials in the same condition.

Other Tianjin Medical University General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07492004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing